Ublituximab Associated With Improvement in Fatigue: Results from ULTIMATE I and II
A study presented at the Consortium of Multiple Sclerosis Centers showed that ublituximab significantly improved fatigue in patients with multiple sclerosis. The research highlighted the impact of MS-related fatigue on patients' quality of life and daily activities. ULTIMATE I and II trials compared
0 views • 14 slides